# L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)

Source: https://onco.cc/trials/nct07227350/  
OnCo record `nct07227350` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of L19IL2 in basal cell carcinoma, run by Philogen S.p.A., now recruiting.

## Summary

L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) is a phase 2 interventional study registered as NCT07227350 by Philogen S.p.A., with 180 participants planned, started 2026-06-01 and due to reach its primary completion in 2031-02. Interventions recorded: L19IL2, L19TNF and L19IL2/L19TNF.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07227350
- Phase: 2
- Setting: A Phase 2 Controlled Randomized Study of the Efficacy of L19IL2 or L19TNF or L19IL2/L19TNF Intralesional Injections for the Treatment of Locally Advanced Basal Cell Carcinoma (LaBCC)
- Sponsor: Philogen S.p.A.
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT07227350: https://clinicaltrials.gov/study/NCT07227350

## Connected records

- cancers: [Basal cell carcinoma](https://onco.cc/cancers/basal-cell-carcinoma/)
- companies: [Philogen S.p.A.](https://onco.cc/companies/philogen-s-p-a/)

---
JSON: https://onco.cc/api/v1/entities/nct07227350.json